Medium impact
Huntington's Disease (CPB 0614, reviewed 2026-02-25)
Aetna·Effective Feb 25, 2026
Aetna has updated its Huntington's Disease clinical policy (CPB 0614, effective 2026-02-25) to designate numerous diagnostic tests, biomarkers, and treatment interventions as experimental, investigational, or unproven. This policy classifies over 40 specific treatments and diagnostic approaches—including gene therapy, stem cell transplantation, deep brain stimulation, various biomarker measurements, and neuroimaging modalities—as non-covered services. Billing teams must immediately deny or require prior authorization for claims using the listed CPT/HCPCS codes when billed for Huntington's disease indications.